KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Shares Outstanding (Diluted Average) (2016 - 2026)

Biogen has reported Shares Outstanding (Diluted Average) over the past 18 years, most recently at $148.4 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 1.23% year-over-year to $148.4 million; the TTM value through Mar 2026 reached $148.4 million, up 1.23%, while the annual FY2025 figure was $147.1 million, 0.82% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $148.4 million at Biogen, up from $147.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $148.4 million in Q1 2026 and troughed at $145.2 million in Q1 2023.
  • A 5-year average of $146.4 million and a median of $146.1 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 3.09% in 2022 and later grew 1.23% in 2026.
  • Year by year, Shares Outstanding (Diluted Average) stood at $146.0 million in 2022, then decreased by 0.27% to $145.6 million in 2023, then rose by 0.21% to $145.9 million in 2024, then grew by 0.82% to $147.1 million in 2025, then grew by 0.88% to $148.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BIIB at $148.4 million in Q1 2026, $147.1 million in Q4 2025, and $147.1 million in Q3 2025.